A once-weekly injection widely used in adult weight management has shown significant benefits in a clinical trial involving children as young as six, raising fresh questions about how doctors may treat severe childhood obesity. The medicine is semaglutide, marketed for weight management as Wegovy. Results from the Phase 3 STEP Young trial were published on November 16, 2026, in the New England Journal of Medicine. Read the study in the New England Journal of Medicine.

What The Trial Discovered
The study enrolled 167 children aged six to under 12 who were living with obesity. Participants were randomly assigned to receive weekly semaglutide injections or a placebo, and both groups also received counselling on lifestyle changes. Researchers assessed body-mass index (BMI), a measure that relates weight to height, with the main comparison made after 68 weeks of treatment. The published trial report details the design and findings.
At week 68, the average BMI among children receiving semaglutide had fallen by 13.5 per cent from the start of the trial. In the placebo group, average BMI increased by 2.7 per cent. The estimated difference between the groups was 16.2 percentage points, a statistically significant result that suggests the medicine had a substantial effect beyond the lifestyle counselling provided to both groups. Study results and statistical analysis.
The researchers also found that 79 per cent of children in the semaglutide group moved into a lower BMI category, compared with 23 per cent of those who received placebo. By week 68, 38 per cent of children taking semaglutide had a BMI below the threshold used to classify obesity for their age and sex, compared with two per cent in the placebo group. These outcomes indicate improvement, although they do not mean every child achieved a healthy weight. Read the trial findings.
How The Medicine Works And What Researchers Observed
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. It acts on pathways involved in appetite and fullness, helping people feel satisfied and reducing food intake. In this trial, the medicine was given as a once-weekly injection alongside a reduced-calorie eating plan and increased physical activity. Novo Nordisk’s STEP Young results summary describes the treatment approach.
Side effects were common in both groups: 96 per cent of children receiving semaglutide and 93 per cent receiving placebo reported adverse events. Gastrointestinal problems were the most frequent and occurred more often among children taking the medicine. They led one participant in the semaglutide group to stop treatment. The researchers said the overall safety pattern was consistent with what has been observed in older patients, but the relatively small number of participants means continued monitoring is important. The journal’s safety findings.
Questions About Growth And Long-Term Effects
The encouraging weight findings do not settle every question about treating young children with powerful appetite-regulating medicines. A report on the research presented around the ObesityWeek 2026 conference noted that children receiving Wegovy grew about 1.3 inches less, on average, than those in the comparison group during the study period. Specialists said more follow-up is needed to determine whether this reflects a change in obesity-associated rapid growth or an effect of the medicine itself. The Wall Street Journal’s report on the findings and expert concerns.
That issue is particularly important because children are still developing. Doctors need to consider height and weight trajectories, nutrition, puberty, psychological wellbeing and possible side effects rather than judging treatment by the number on a scale alone. The STEP Young investigators also reported results after a longer treatment period, but the study was not designed to answer every question about health outcomes over many years. See the study’s follow-up data and limitations.
Does This Mean Wegovy Is Now Approved For Six-Year-Olds?
No. Evidence that a medicine works in a clinical trial is not the same as regulatory approval for a new age group. The published study evaluated children aged six to under 12, but parents should not interpret the findings as permission to obtain or administer semaglutide to a young child. The treatment’s authorised age range and prescribing conditions depend on the regulator and the current product label in each country. Consult the current US prescribing information and instructions.
Any decision about obesity treatment in a child must be made by a qualified paediatric clinician after an individual assessment. Families should not use adult weight-loss prescriptions, share medication or adjust doses without medical direction. Lifestyle support, adequate nutrition, physical activity, sleep and assessment for medical or genetic contributors remain important parts of childhood obesity care.
A Promising Result, With Caution Still Needed
The STEP Young trial adds important evidence to a field where treatment options for younger children have been limited. Its results suggest semaglutide can produce a meaningful reduction in BMI among children with obesity, but questions about growth, long-term safety, access and appropriate patient selection remain. The research was funded by Novo Nordisk, the manufacturer of Wegovy, and the findings will need to be considered alongside further independent evidence and regulatory review. Read the peer-reviewed study and the manufacturer’s announcement.